Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $11.0 million.

  • Nurix Therapeutics' Change in Accured Expenses rose 2236.26% to $11.0 million in Q4 2025 from the same period last year, while for Nov 2025 it was $17.3 million, marking a year-over-year increase of 4649.63%. This contributed to the annual value of $17.3 million for FY2025, which is 4649.63% up from last year.
  • According to the latest figures from Q4 2025, Nurix Therapeutics' Change in Accured Expenses is $11.0 million, which was up 2236.26% from $6.3 million recorded in Q3 2025.
  • Over the past 5 years, Nurix Therapeutics' Change in Accured Expenses peaked at $11.0 million during Q4 2025, and registered a low of -$7.0 million during Q2 2025.
  • Its 5-year average for Change in Accured Expenses is $2.3 million, with a median of $3.3 million in 2021.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 31468.02% in 2022, then plummeted by 40287.87% in 2024.
  • Nurix Therapeutics' Change in Accured Expenses (Quarter) stood at $3.4 million in 2021, then fell by 2.51% to $3.3 million in 2022, then fell by 6.71% to $3.1 million in 2023, then soared by 193.46% to $9.0 million in 2024, then grew by 22.36% to $11.0 million in 2025.
  • Its Change in Accured Expenses was $11.0 million in Q4 2025, compared to $6.3 million in Q3 2025 and -$7.0 million in Q2 2025.